- Home
- AKA vs CRDL Comparison
AKA vs CRDL Comparison
Compare AKA & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- CRDL
- Stock Information
- Founded
- AKA 2018
- CRDL 2017
- Country
- AKA United States
- CRDL Canada
- Employees
- AKA N/A
- CRDL N/A
- Industry
- AKA Catalog/Specialty Distribution
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKA Consumer Discretionary
- CRDL Health Care
- Exchange
- AKA Nasdaq
- CRDL Nasdaq
- Market Cap
- AKA 110.4M
- CRDL 112.4M
- IPO Year
- AKA 2021
- CRDL N/A
- Fundamental
- Price
- AKA $11.01
- CRDL $1.44
- Analyst Decision
- AKA Buy
- CRDL Strong Buy
- Analyst Count
- AKA 4
- CRDL 2
- Target Price
- AKA $22.50
- CRDL $9.00
- AVG Volume (30 Days)
- AKA 5.4K
- CRDL 289.4K
- Earning Date
- AKA 08-06-2025
- CRDL 08-11-2025
- Dividend Yield
- AKA N/A
- CRDL N/A
- EPS Growth
- AKA N/A
- CRDL N/A
- EPS
- AKA N/A
- CRDL N/A
- Revenue
- AKA $586,514,000.00
- CRDL N/A
- Revenue This Year
- AKA $6.60
- CRDL N/A
- Revenue Next Year
- AKA $4.14
- CRDL N/A
- P/E Ratio
- AKA N/A
- CRDL N/A
- Revenue Growth
- AKA 8.09
- CRDL N/A
- 52 Week Low
- AKA $7.00
- CRDL $0.77
- 52 Week High
- AKA $32.25
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- AKA 46.25
- CRDL 56.90
- Support Level
- AKA $10.75
- CRDL $1.14
- Resistance Level
- AKA $11.54
- CRDL $1.42
- Average True Range (ATR)
- AKA 0.40
- CRDL 0.10
- MACD
- AKA 0.04
- CRDL 0.01
- Stochastic Oscillator
- AKA 22.47
- CRDL 83.33
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.